Lowering dose of d4T can maintain efficacy and reduce side effects
6 September 2004. Related: Conference reports, Antiretrovirals.
Conference reports
Three-year renal safety with tenofovir; cystatin may be a useful marker
6 September 2004. Related: Conference reports, Side effects.
Fluconazole increases nevirapine levels and risk of serious hepatotoxicity
6 September 2004. Related: Conference reports, PK and drug interactions.
Efavirenz interaction with rifampin may not require dose adjustment in patients with low body weight
6 September 2004. Related: Conference reports, PK and drug interactions.
Tipranavir significantly lowers doses of saquinavir, amprenavir and lopinavir/r
6 September 2004. Related: Conference reports, PK and drug interactions.
Responses to hepatitis vaccinations: an optimum window for protection?
6 September 2004. Related: Conference reports, Hepatitis coinfection.
HBV vaccine, CD4 count and increasing response with double-dose
6 September 2004. Related: Conference reports, Coinfections and complications, Hepatitis coinfection.
Response to Hepatitis A (HAV) vaccine determined by CD4 count
6 September 2004. Related: Conference reports, Hepatitis coinfection.
Inventive ways to explain HAART and adherence to children
6 September 2004. Related: Conference reports, Paediatric care.
Isoniazid has early and unexpected benefit in reducing childhood mortality
6 September 2004. Related: Conference reports, Paediatric care.
Lack of keratin overlaying inner foreskin may explain lower HIV infection rates in circumcised men
6 September 2004. Related: Conference reports, HIV prevention and transmission.
XIII International HIV Resistance Workshop 8-12 June 2004, Tenerife
29 July 2004. Related: Conference reports.
Risk of NNRTI-resistance during STI: implications for SMART and other STI studies
29 July 2004. Related: Conference reports, Drug resistance.
Persistent nevirapine resistance following mother to child transmission interventions
29 July 2004. Related: Conference reports, Pregnancy, Drug resistance.
Tipranavir resistance and viral response: L90M did not reduce response, recommendation to use with T-20
29 July 2004. Related: Conference reports, Pregnancy, Drug resistance, Other news.
Resistance in the UK: new approach to epidemiological studies
29 July 2004. Related: Conference reports, Drug resistance.
Low AZT activity against HIV-2 infection
29 July 2004. Related: Conference reports, Drug resistance.
No evidence for cross resistance between nevirapine and d4T
29 July 2004. Related: Conference reports, Drug resistance.
Experimental compounds to target viral expression in latent cells
29 July 2004. Related: Conference reports, Antiretrovirals, Drug resistance.
Case of MDR reinfection with MDR virus
29 July 2004. Related: Conference reports, Drug resistance.
Keystone HIV Pathogenesis and Vaccine Development Report 12-18 April 2004, Whistler, British Columbia, Canada
29 July 2004. Related: Conference reports.
Keystone HIV Pathogenesis and Vaccine Report
29 July 2004. Related: Conference reports, Basic science and immunology, Vaccines and microbicides.
10th Anniversary Conference of the British HIV Association (BHIVA), 15–17 April 2004, Cardiff
2 June 2004. Related: Conference reports.
BHIVA 2003-4 audit on HIV and pregnancy
2 June 2004. Related: Conference reports.
More positive children are surviving into adult life and require tailored services
2 June 2004. Related: Conference reports, Paediatric care.
Other news from 10th BHIVA conference
2 June 2004. Related: Conference reports.
5th International Workshop on Clinical Pharmacology of HIV Therapy, 1-3 April 2004, Rome, Italy
2 May 2004. Related: Conference reports, PK and drug interactions.
Large reductions in plasma PK levels of saquinavir, amprenavir and lopinavir/r levels when given with tipranavir/ritonavir
2 May 2004. Related: Conference reports, PK and drug interactions.
Good generic drugs and good adherence in Rwanda
2 May 2004. Related: Conference reports, Treatment access, PK and drug interactions.
Steady state PK of nelfinavir and M8 in pregnancy
2 May 2004. Related: Conference reports, Pregnancy, PK and drug interactions, TB coinfection.
Higher nelfinavir concentrations improve response in children
2 May 2004. Related: Conference reports, Paediatric care, PK and drug interactions.
PK of once daily lopinavir/r in children
2 May 2004. Related: Conference reports, Paediatric care, PK and drug interactions.
2nd European HIV Drug Resistance Workshop, 11-13 March 2004, Rome, Italy
2 May 2004. Related: Conference reports.
Understanding developments in HIV drug resistance for new drugs and targets — atazanavir, fusion (T-20) and receptor inhibitors
2 May 2004. Related: Conference reports, Drug resistance.
11th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2004, San Francisco
2 May 2004. Related: Conference reports.
HIV-associated dementia and cognitive dysfunction
2 May 2004. Related: Conference reports, Coinfections and complications.
Diabetes and HIV and HCV; aging/HIV and diabetes
2 May 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
11th Conference on Retroviruses and Opportunistic Infections (CROI)
3 April 2004. Related: Conference reports.
Drug levels can persist for more than two weeks after stopping efavirenz
3 April 2004. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Race affects absorption and clearance of efavirenz
3 April 2004. Related: Conference reports, PK and drug interactions, Side effects.
Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination
3 April 2004. Related: Conference reports, PK and drug interactions.
Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome
3 April 2004. Related: Conference reports, PK and drug interactions.
Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T
3 April 2004. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation
3 April 2004. Related: Conference reports, Antiretrovirals.
Studies of new pipeline drugs
3 April 2004. Related: Conference reports, Antiretrovirals.
Little benefit seen for treatment during acute infection
3 April 2004. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Summary of resistance studies at Retrovirus
3 April 2004. Related: Conference reports, Drug resistance.
Update on peripheral neuropathy in HIV-infection
3 April 2004. Related: Conference reports, Side effects.
Smoking marijuana provides analgesic effect on HIV neuropathy
3 April 2004. Related: Conference reports, Side effects.
Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure
3 April 2004. Related: Conference reports, Side effects.
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Rosiglitazone shows no benefit for lipoatrophy
2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Hypertension related to HAART in HIV-positive women
2 April 2004. Related: Conference reports, Women's health.
Testosterone therapy for women with low androgen levels or body weight
2 April 2004. Related: Conference reports, Women's health.
Nevirapine, pregnancy and adverse events
2 April 2004. Related: Conference reports, Pregnancy.
Prior nevirapine exposure for pregnant women can contribute to treatment failure
2 April 2004. Related: Conference reports.
Conflicting findings with HAART use in pregnancy and prematurity
2 April 2004. Related: Conference reports, Pregnancy.
Antiretrovirals, mode of delivery and transmission risk
2 April 2004. Related: Conference reports, Pregnancy.
Tenofovir studies in children
2 April 2004. Related: Conference reports, Paediatric care.
Increase of non-AIDS defining cancers in HOPS cohort
2 April 2004. Related: Conference reports, Cancer and HIV.
HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1
2 April 2004. Related: Conference reports, Hepatitis coinfection.
Epoetin-alfa improves interferon/ribavirin-associated anaemia
2 April 2004. Related: Conference reports, Hepatitis coinfection.
9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw
1 December 2003. Related: Conference reports.
Lower doses of d4T produce similar efficacy and reduced side effects
1 December 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching from efavirenz to nevirapine to avoid CNS side effects
1 December 2003. Related: Conference reports, Antiretrovirals, Side effects.